Last reviewed · How we verify
Recombinant LH (Luveris)
Recombinant luteinizing hormone (LH) stimulates the ovaries to produce estrogen and progesterone, promoting follicle development and ovulation in women with LH deficiency.
Recombinant luteinizing hormone (LH) stimulates the ovaries to produce estrogen and progesterone, promoting follicle development and ovulation in women with LH deficiency. Used for Infertility in women with LH and FSH deficiency undergoing assisted reproductive technology, Anovulation or oligo-ovulation in women with hypogonadotropic hypogonadism.
At a glance
| Generic name | Recombinant LH (Luveris) |
|---|---|
| Also known as | Luveris |
| Sponsor | Azienda Ospedaliero-Universitaria di Modena |
| Drug class | Gonadotropin; recombinant hormone |
| Target | Luteinizing hormone receptor (LHCGR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive endocrinology; Fertility |
| Phase | FDA-approved |
Mechanism of action
Luveris is a recombinant form of human luteinizing hormone that binds to LH receptors on ovarian theca cells, stimulating androgen production which is converted to estrogen by granulosa cells. It is used in combination with follicle-stimulating hormone (FSH) to support controlled ovarian hyperstimulation in assisted reproductive technology. This hormone replacement approach is particularly valuable in women with hypogonadotropic hypogonadism or those requiring exogenous LH supplementation during fertility treatment.
Approved indications
- Infertility in women with LH and FSH deficiency undergoing assisted reproductive technology
- Anovulation or oligo-ovulation in women with hypogonadotropic hypogonadism
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/discomfort
- Nausea
Key clinical trials
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment (NA)
- Extended LH Administration (PHASE2)
- Recombinant LH Prior to Ovarian Stimulation in Poor Ovarian Responders (PRE-LH) (PHASE3)
- Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment (PHASE4)
- Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders (PHASE4)
- Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men (PHASE2)
- Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant LH (Luveris) CI brief — competitive landscape report
- Recombinant LH (Luveris) updates RSS · CI watch RSS
- Azienda Ospedaliero-Universitaria di Modena portfolio CI